Our Mission is Clear
and Simple

NewAmsterdam was co-founded by world renowned lipidologist Professor Dr. John Kastelein and venture capital firm Forbion.

Acquired all rights for obicetrapib, a novel, selective cholesteryl ester transfer protein (CETP) inhibitor, from a subsidiary of Amgen.

Dr. Michael Davidson, a leading lipidologist and cardiologist, joined as co-founding Chief Executive Officer.

Completed a $196M (€160M) Series A funding round to initiate obicetrapib’s Phase 3 clinical development program.

Presented full data from Phase 2 ROSE trial at AHA Scientific Sessions.

Dosed first patients in Phase 3 BROADWAY trial and Phase 3 PREVAIL trial.

Signed a licensing deal with the Menarini Group to commercialize obicetrapib in Europe with a total potential deal value of more than €1 billion.

Dosed first patient in Phase 3 BROOKLYN trial.

Debuted on the Nasdaq as publicly traded company (Nasdaq: NAMS) and raised $328 million in gross proceeds.

Presented full data from Phase 2 ROSE2 trial at NLA Scientific Sessions.

Began evolution into a powerful commercial organization with appointment of first Chief Commercial Officer, B.J. Jones.

Generated net proceeds of $190 million via an upsized public offering to support obicetrapib’s continued development and ongoing commercial readiness.

Dosed first patient in Phase 3 fixed-dose combination TANDEM trial.

Completed enrollment in Phase 3 cardiovascular outcomes trial, PREVAIL.

Completed enrollment in Phase 3 fixed-dose combination TANDEM trial.

Topline data announced from Phase 3 BROOKLYN trial.

Presented full data from Phase 3 BROOKLYN trial at AHA Scientific Sessions 2024.

Topline data announced for Phase 3 TANDEM trial.

Topline data announced for Phase 3 BROADWAY trial.

Announced the closing of $479.0M worth public offerings of ordinary shares and pre-funded warrants.